Q2 U.S. Galleri Revenue Grew 21% Year-Over-Year to $34.2 Million Q2 Galleri Tests Sold Grew 29% Year-Over-Year to More Than 45,000 Detailed Results From First 25,000 Enrolled in PATHFINDER 2 to be Submitted for Presentation at ESMO 2025 in October MENLO PARK, Calif., Aug. 12, 2025...
Related Questions
How will the 21% YoY revenue growth for Galleri impact GRAIL's valuation multiples?
What is the market's reaction to the 29% YoY increase in Galleri test volume, and how might that affect the stock price?
What guidance, if any, did management provide for Q3 and full-year 2025 revenue and test volumes?
How does the growth in Galleri revenue and test volume translate to profitability and cash flow?
What is the cost structure of the Galleri test and expected margin expansion?
Will the forthcoming PATHFINDER 2 results presented at ESMO 2025 affect analyst expectations?
What are the competitive risks from other companies developing multi-cancer early detection tests?
What are the potential impacts on GRAIL's long‑term growth trajectory and market share in the early‑detection market?
How does GRAIL's Q2 performance compare to other liquid biopsy and early cancer detection companies?
How might regulatory developments or reimbursement changes affect future revenue?